This document provides a sum-of-parts fair value analysis for ARIAD Pharmaceuticals, Inc., detailing the peak sales, stage of development, estimated launch date, probability of commercialization, percentage of sales to the company, probability-adjusted NPV, value per share, and percentage of fair value for different drugs. It includes financial estimates and valuations by William Blair & Company, LLC.
doj/DataSet10/EFTA01450729.pdf
{"title":"ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value","key_people":["Y. Katherine Xu, Ph.D."],"document_type":"tabular","document_subtype":"financial analysis","key_organizations":["William Blair & Company, LLC","ARIAD Pharmaceuticals, Inc."],"reference_numbers":["DB-SDNY-0106554","SDNY_GM_00252738","EFTA01450729"]}